Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa.
Matsumura W, Fujita Y, Shinkuma S, Suzuki S, Yokoshiki S, Goto H, Hayashi H, Ono K, Inoie M, Takashima S, Nakayama C, Nomura T, Nakamura H, Abe R, Sato N, Shimizu H. Matsumura W, et al. Among authors: sato n. J Invest Dermatol. 2019 Oct;139(10):2115-2124.e11. doi: 10.1016/j.jid.2019.03.1155. Epub 2019 May 2. J Invest Dermatol. 2019. PMID: 31054844 Free article. Review.
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Yamaguchi K, Takeda Y, Goto H, Sato N, Koizumi K, Mukai M, Koike T. Nishio M, et al. Among authors: sato n. Br J Haematol. 2007 May;137(4):349-54. doi: 10.1111/j.1365-2141.2007.06584.x. Br J Haematol. 2007. PMID: 17456057 Free article.
FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N, Koike T. Nishio M, et al. Among authors: sato n. Eur J Haematol. 2009 Feb;82(2):143-7. doi: 10.1111/j.1600-0609.2008.01174.x. Epub 2008 Nov 6. Eur J Haematol. 2009. PMID: 19018870
HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.
Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Sato N, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H. Ujiie H, et al. Among authors: sato n. J Invest Dermatol. 2018 May;138(5):1201-1204. doi: 10.1016/j.jid.2017.11.023. Epub 2017 Dec 2. J Invest Dermatol. 2018. PMID: 29203362 Free article. No abstract available.
Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan.
Yamada K, Shiraishi H, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Ono K, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Yamada K, et al. Among authors: sato n. Mol Genet Metab Rep. 2018 Feb 22;15:55-63. doi: 10.1016/j.ymgmr.2018.02.003. eCollection 2018 Jun. Mol Genet Metab Rep. 2018. PMID: 29552494 Free PMC article.
Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial.
Otagiri S, Ohnishi S, Miura A, Hayashi H, Kumagai I, Ito YM, Katsurada T, Nakamura S, Okamoto R, Yamahara K, Cho KY, Isoe T, Sato N, Sakamoto N. Otagiri S, et al. Among authors: sato n. BMJ Open Gastroenterol. 2018 May 31;5(1):e000206. doi: 10.1136/bmjgast-2018-000206. eCollection 2018. BMJ Open Gastroenterol. 2018. PMID: 29915666 Free PMC article.
Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial.
Yamahara K, Hamada A, Soma T, Okamoto R, Okada M, Yoshihara S, Yoshihara K, Ikegame K, Tamaki H, Kaida K, Inoue T, Ohsugi Y, Nishikawa H, Hayashi H, Ito YM, Iijima H, Ohnishi S, Hashimoto D, Isoe T, Teshima T, Ogawa H, Sato N, Fujimori Y. Yamahara K, et al. Among authors: sato n. BMJ Open. 2019 Jul 9;9(7):e026403. doi: 10.1136/bmjopen-2018-026403. BMJ Open. 2019. PMID: 31289066 Free PMC article.
Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey.
Shiraishi H, Yamada K, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, Kuzume K, Watanabe K, Sameshima K, Nakamagoe K, Tamaoka A, Asahina N, Yokoshiki S, Miyakoshi T, Oba K, Isoe T, Hayashi H, Yamaguchi S, Sato N. Shiraishi H, et al. Among authors: sato n. Mol Genet Metab Rep. 2019 Jul 25;20:100496. doi: 10.1016/j.ymgmr.2019.100496. eCollection 2019 Sep. Mol Genet Metab Rep. 2019. PMID: 31372341 Free PMC article.
5,363 results